Literature DB >> 21802000

Size effect in molecular imaging of vascular endothelial growth factor.

Gang Niu1, Xiaoyuan Chen.   

Abstract

Visualizing and quantifying vascular endothelial growth factor (VEGF) levels are crucial factors in understanding the tumor environment and monitoring antiangiogenic treatment. The small peptidic probes described by Fedorova et al. in this issue appear to be superior to antibodies in reflecting the dynamics of VEGF as they facilitate image quantification.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2011        PMID： 21802000      PMCID： PMC3629963          DOI： 10.1016/j.chembiol.2011.07.002

Source DB:  PubMed          Journal:  Chem Biol        ISSN： 1074-5521


  8 in total

1.  Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.

Authors:  Bishnuhari Paudyal; Pramila Paudyal; Noboru Oriuchi; Hirofumi Hanaoka; Hideyuki Tominaga; Keigo Endo
Journal:  Cancer Sci       Date:  2010-11-10       Impact factor: 6.716

2.  The development of peptide-based tools for the analysis of angiogenesis.

Authors:  Anna Fedorova; Kerry Zobel; Herman S Gill; Annie Ogasawara; Judith E Flores; Jeff N Tinianow; Alexander N Vanderbilt; Ping Wu; Y Gloria Meng; Simon-P Williams; Christian Wiesmann; Jeremy Murray; Jan Marik; Kurt Deshayes
Journal:  Chem Biol       Date:  2011-07-29

3.  VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.

Authors:  Wouter B Nagengast; Marjolijn N Lub-de Hooge; Sjoukje F Oosting; Wilfred F A den Dunnen; Frank-Jan Warnders; Adrienne H Brouwers; Johan R de Jong; Patricia M Price; Harry Hollema; Geke A P Hospers; Philip H Elsinga; Jan Willem Hesselink; Jourik A Gietema; Elisabeth G E de Vries
Journal:  Cancer Res       Date:  2010-11-17       Impact factor: 12.701

4.  111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.

Authors:  Ingrid M E Desar; Alexander B Stillebroer; Egbert Oosterwijk; William P J Leenders; Carla M L van Herpen; Winette T A van der Graaf; Otto C Boerman; Peter F A Mulders; Wim J G Oyen
Journal:  J Nucl Med       Date:  2010-10-18       Impact factor: 10.057

Review 5.  Tumorigenesis and the angiogenic switch.

Authors:  Gabriele Bergers; Laura E Benjamin
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

Review 6.  Molecular basis for sunitinib efficacy and future clinical development.

Authors:  Sandrine Faivre; George Demetri; William Sargent; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

7.  PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.

Authors:  Gang Niu; Zibo Li; Jin Xie; Quynh-Thu Le; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

Review 8.  Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.

Authors:  Gang Niu; Xiaoyuan Chen
Journal:  Curr Drug Targets       Date:  2010-08       Impact factor: 3.465
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.